Adenosine monophosphate deaminase deficiency

Adenosine monophosphate deaminase deficiency (AMP deaminase deficiency), also known as myoadenylate deaminase deficiency (MAD deficiency) or AMPD1 deficiency, is a metabolic myopathy caused by a deficiency of the enzyme myoadenylate deaminase (AMP deaminase 1) in skeletal muscle. This enzyme plays a critical role in the purine nucleotide cycle, which is essential for energy metabolism during exercise. When the enzyme is deficient, the muscle's ability to generate energy during vigorous physical activity is impaired, leading to exercise-related symptoms. The condition primarily affects the skeletal muscular system. Key clinical features include exercise-induced muscle pain (myalgia), early fatigue, muscle cramping, and occasionally myoglobinuria following strenuous physical activity. However, the clinical significance of this deficiency is debated, as many individuals carrying the common causative mutation (a C34T variant in the AMPD1 gene) remain completely asymptomatic throughout life. Some affected individuals may experience progressive muscle weakness over time. The condition can present as a primary (inherited) form or as a secondary form associated with other neuromuscular disorders. There is currently no specific curative treatment for AMP deaminase deficiency. Management is primarily supportive and focuses on lifestyle modifications, including avoidance of strenuous exercise that triggers symptoms, pacing of physical activities, and symptomatic relief of muscle pain. Some studies have explored the use of ribose supplementation to support energy metabolism in muscle, though evidence for its efficacy remains limited. Patients are generally advised to work with a neuromuscular specialist for monitoring and individualized management strategies.

Common questions about Adenosine monophosphate deaminase deficiency